PURPOSE: To discuss the pathological and clinical characteristics, treatments and prognosis of chromophobe renal cell carcinoma (CRCC). METHODS: We developed a database that contained 1,870 patients who were diagnosed with renal cell carcinoma (RCC) and who underwent surgery in our hospital between 2002 and 2010. Afterward, the clinical and pathological data of 53 CRCC cases were extracted and analyzed. RESULTS: The mean age of the 53 patients at diagnosis was 50.2 years (range, 21-88 years), and the ratio of male to female was 1:1. All tumors were unilateral and a majority of them (69.8%) were discovered incidentally. The mean tumor size was 5.8 ± 3.2 cm (range, 2-20 cm). Stage T1, T2, and T3 tumors, in accordance with 2004 TNM classification, accounted for 75.5, 13.2 and 11.3% of all cases, respectively. By histologic grading, 11.3, 73.6 and 15.1% of the tumors were G1, G2, and G3, respectively. Forty-one (77.4%) patients underwent radical nephrectomy, 12 (22.6%) underwent partial nephrectomy. Forty-five (84.9%) patients with follow-up results were alive after a mean follow-up of 34 months (range, 4-79 months). Tumor metastasis was discovered in 2 patients: one tumor metastasis was found in the liver 4 months postoperation, and the other was found in the lumbar vertebrae 47 months postoperation. No local recurrence was found. The overall survival rate was 100%. CONCLUSIONS: CRCC is an uncommon subtype of RCC, with a favorable prognosis. Chinese patients are seemingly younger at diagnosis. Prediction of prognosis is still difficult.
PURPOSE: To discuss the pathological and clinical characteristics, treatments and prognosis of chromophobe renal cell carcinoma (CRCC). METHODS: We developed a database that contained 1,870 patients who were diagnosed with renal cell carcinoma (RCC) and who underwent surgery in our hospital between 2002 and 2010. Afterward, the clinical and pathological data of 53 CRCC cases were extracted and analyzed. RESULTS: The mean age of the 53 patients at diagnosis was 50.2 years (range, 21-88 years), and the ratio of male to female was 1:1. All tumors were unilateral and a majority of them (69.8%) were discovered incidentally. The mean tumor size was 5.8 ± 3.2 cm (range, 2-20 cm). Stage T1, T2, and T3 tumors, in accordance with 2004 TNM classification, accounted for 75.5, 13.2 and 11.3% of all cases, respectively. By histologic grading, 11.3, 73.6 and 15.1% of the tumors were G1, G2, and G3, respectively. Forty-one (77.4%) patients underwent radical nephrectomy, 12 (22.6%) underwent partial nephrectomy. Forty-five (84.9%) patients with follow-up results were alive after a mean follow-up of 34 months (range, 4-79 months). Tumor metastasis was discovered in 2 patients: one tumor metastasis was found in the liver 4 months postoperation, and the other was found in the lumbar vertebrae 47 months postoperation. No local recurrence was found. The overall survival rate was 100%. CONCLUSIONS: CRCC is an uncommon subtype of RCC, with a favorable prognosis. Chinese patients are seemingly younger at diagnosis. Prediction of prognosis is still difficult.
Authors: Luca Cindolo; Alexandre de la Taille; Luigi Schips; Richard E Zigeuner; Vincenzo Ficarra; Jacques Tostain; Walter Artibani; Antonio Gallo; Luigi Salzano; Jean-Jacques Patard Journal: Urology Date: 2005-04 Impact factor: 2.649
Authors: Kyle A Furge; Kerry A Lucas; Masayuki Takahashi; Jun Sugimura; Eric J Kort; Hiro-omi Kanayama; Susumu Kagawa; Philip Hoekstra; John Curry; Ximing J Yang; Bin T Teh Journal: Cancer Res Date: 2004-06-15 Impact factor: 12.701
Authors: Tobias Klatte; Ken-ryu Han; Jonathan W Said; Malte Böhm; Ernst Peter Allhoff; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck Journal: Urol Oncol Date: 2008-01-14 Impact factor: 3.498
Authors: Michaël Peyromaure; Vincent Misrai; Nicolas Thiounn; Annick Vieillefond; Marc Zerbib; Thierry A Flam; Bernard Debré Journal: Cancer Date: 2004-04-01 Impact factor: 6.860
Authors: Maria V Yusenko; Roland P Kuiper; Tamas Boethe; Börje Ljungberg; Ad Geurts van Kessel; Gyula Kovacs Journal: BMC Cancer Date: 2009-05-18 Impact factor: 4.430
Authors: M May; R Zigeuner; A Aziz; L Cindolo; C Gilfrich; L Schips; O De Cobelli; B Rocco; C De Nunzio; A Tubaro; I Coman; B Feciche; M Truss; B Hoschke; O Dalpiaz; A Stoltze; F Fenske; H-M Fritsche; T Chromecki; S Lebentrau; R S Figenshau; K Madison; M Sánchez-Chapado; M Del Carmen Santiago Martin; L Salzano; G Lotrecchiano; S Joniau; R Waidelich; C G Stief; S Brookman-May Journal: Urologe A Date: 2014-02 Impact factor: 0.639
Authors: Jozefina Casuscelli; Maria F Becerra; Kenneth Seier; Brandon J Manley; Nicole Benfante; Almedina Redzematovic; Christian G Stief; James J Hsieh; Satish K Tickoo; Victor E Reuter; Jonathan A Coleman; Paul Russo; Irina Ostrovnaya; A Ari Hakimi Journal: Clin Genitourin Cancer Date: 2019-06-26 Impact factor: 2.872
Authors: Abhishek Maiti; Robert E Brown; Paul G Corn; Ravi Murthy; Dhakshina Moorthy Ganeshan; Apostolia M Tsimberidou; Vivek Subbiah Journal: Clin Genitourin Cancer Date: 2015-11-11 Impact factor: 2.872